Metabolic syndrome and coronary angiographic disease progression: the Women’s Angiographic Vitamin & Estrogen trial
- 30 September 2003
- journal article
- clinical trial
- Published by Elsevier in American Heart Journal
- Vol. 146 (3), 439-445
- https://doi.org/10.1016/s0002-8703(03)00227-8
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final ReportCirculation, 2002
- Women's Angiographic Vitamin and Estrogen trial:Controlled Clinical Trials, 2002
- Effects of Hormone Replacement Therapy and Antioxidant Vitamin Supplements on Coronary Atherosclerosis in Postmenopausal WomenJAMA, 2002
- Prevalence of the Metabolic Syndrome Among US AdultsJAMA, 2002
- Influence of Low High-Density Lipoprotein Cholesterol and Elevated Triglyceride on Coronary Heart Disease Events and Response to Simvastatin Therapy in 4SCirculation, 2001
- Simvastatin and Niacin, Antioxidant Vitamins, or the Combination for the Prevention of Coronary DiseaseNew England Journal of Medicine, 2001
- Cardiovascular Morbidity and Mortality Associated With the Metabolic SyndromeDiabetes Care, 2001
- Lipid-lowering interventions in angiographic trialsThe American Journal of Cardiology, 1995
- Development of new coronary atherosclerotic lesions during a 4-year multifactor risk reduction program: The stanford coronary risk intervention project (SCRIP)Journal of the American College of Cardiology, 1994
- Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial.Circulation, 1994